This International Clinical Trials Day, Saturday 20 May, we’re shining a spotlight on one of the latest studies taking place at Peninsula Health, the ‘Evaluation of the safety and efficacy of extracorporeal carbon dioxide removal in the critically ill using PrismaLung.’
The study began in March 2022 at Frankston Hospital. Trialing a new minimally invasive device used for the treatment of patients with severe respiratory (lung) failure in intensive care units.
Named PrismaLung+, the device is designed to help remove excess carbon-dioxide from the lungs of these critically ill patients, as the accumulation of excess carbon dioxide can often be fatal.
“We’re the first hospital in Australia and New Zealand and perhaps in the Southern Hemisphere to trial this device,” says Professor Ravindranath Tiruvoipati, Consultant Intensivist and Director of Intensive Care Research at Peninsula Health.
“This device is likely to be used in many other hospitals in the coming few months, it’s wonderful to lead the introduction of this device into Australia right here at Frankston Hospital.”
The research presented in the study is the first official data on PrismaLung+ and provides insight into how the device can be used, what its potential efficacy is, and what complications may arise from using the device in practice.
Such evidence will help clinicians learn about the device and allow other hospitals to introduce it to their health service.
The study was recently awarded the ‘2023 Safety and Quality Paper Prize’ at this year’s ANZICS/ACCCN Intensive Care Annual Scientific Meeting in Adelaide, and its findings soon to be published in a peer reviewed journal.
Congratulations to Professor Ravindranath Tiruvoipati, and all the other health professionals involved in the study, we thank you for all your hard work, dedication and commitment to improving healthcare outcomes not only here at Peninsula Health but globally as well.